文献速递前列腺癌

穿刺前双参数磁共振成像联合前列腺特异性抗原密度在初诊男性中检测与排除Gleason 7-10前列腺癌

Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
PubMed 文献 · Eur Urol Oncol · 2018-09-27

本研究前瞻性纳入808例临床怀疑局限性前列腺癌的初诊男性,评估双参数磁共振成像(bpMRI)联合前列腺特异性抗原密度(PSAd)检测和排除Gleason评分≥7显著性前列腺癌的诊断准确性。将穿刺限制于bpMRI高度可疑(评分≥4)或PSAd≥0.15ng/ml/cc的男性,可减少41%的穿刺需求和45%的无关癌症过度诊断,仅漏诊5%的显著性前列腺癌。

要点

  • bpMRI联合PSAd可提高初诊男性显著性前列腺癌的诊断准确性和预测值。
  • 将穿刺限制于bpMRI评分≥4或PSAd≥0.15ng/ml/cc的男性可减少41%穿刺需求。
  • 该策略减少45%无关癌症过度诊断,仅漏诊5%显著性前列腺癌。

核心结论

  • bpMRI联合PSAd可改善初诊男性显著性前列腺癌检测的诊断准确性和预测值。
  • 将穿刺限制于bpMRI高度可疑(评分≥4)或PSAd≥0.15ng/ml/cc的男性是本患者队列中的最佳穿刺策略,有效平衡了风险与获益。
  • 需要在其他患者人群中验证本研究结果。

研究设计与样本

  • 前瞻性纳入2015年11月至2017年6月间808例临床怀疑局限性前列腺癌的初诊男性(前列腺特异性抗原<20ng/ml,直肠指检<cT3)。
  • 所有男性先行bpMRI(T2加权和扩散加权成像),随后对任何可疑bpMRI发现进行标准穿刺和靶向穿刺。
  • 以所有男性的联合穿刺结果为参考标准。

主要发现

  • 808例男性中检测到283例(35%)显著性前列腺癌,中位年龄65岁(四分位距60-70),中位PSA 6.9ng/ml(四分位距5.4-9.5)。
  • PSAd显著影响bpMRI检测和排除显著性前列腺癌的预测值。
  • 将穿刺限制于bpMRI高度可疑(评分≥4)或PSAd≥0.15ng/ml/cc的男性,使需要穿刺的男性数量减少41%(329/808),无关癌症过度诊断减少45%(79/177),仅漏诊5%(17/329)的显著性前列腺癌男性。

关键数值与推荐

  • 最佳策略为将穿刺限制于bpMRI高度可疑(评分≥4)或PSAd≥0.15ng/ml/cc的男性。

临床怎么用

  • 对于临床怀疑前列腺癌的初诊男性,若bpMRI结果为低或不确定可疑且PSAd低,可能不需要立即进行前列腺穿刺。

局限性

  • 单中心分析。
  • 以联合穿刺作为参考标准。
  • 需要在其他患者人群中验证本研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiparametric magnetic resonance imaging (MRI) combined with prostate-specific-antigen density (PSAd) enhances the detection of significant prostate cancer (sPCa). However, it is unclear whether simple biparametric (bp) MRI, which reduces scan sequences, time, and cost, may be an equally effective noninvasive tool for detecting and ruling out sPCa and avoiding biopsies in biopsy-naïve men. OBJECTIVE: To assess the diagnostic accuracy, predictive values, and best biopsy strategy combining bpMRI and PSAd in detecting and ruling out sPCa (Gleason score ≥7). DESIGN, SETTING, AND PARTICIPANTS: Assessment of 808 biopsy-naïve men with clinical suspicion of localised PCa (prostate-specific antigen <20ng/ml, rectal examination <cT3), prospectively enrolled between November 2015 and June 2017. INTERVENTION: All men underwent upfront bpMRI (T2- and diffusion-weighted imaging) followed by standard and targeted biopsies of any suspicious bpMRI findings. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Various bpMRI scores and PSAd thresholds were assessed using sPCa detection rates, predictive values, and proportion of biopsies avoided. Net benefits and decision curve analyses were compared. Combined biopsies from all men were used for reference. RESULTS AND LIMITATIONS: Significant prostate cancers were detected in 283/808 (35%) men with median age and PSA (interquartile range) of 65 yr (60-70) and 6.9ng/ml (5.4-9.5), respectively. PSAd significantly influenced the predictive values of bpMRI in detecting and ruling out sPCa. The best strategy was restricting biopsies to men with highly suspicious bpMRI findings (score ≥4) or PSAd ≥0.15ng/ml/cc. This reduced the number of men requiring biopsies by 41% (329/808) and overdiagnosis of insignificant cancers by 45% (79/177), while missing only 5% (17/329) of men with sPCa. Study limitations included single-centre analysis and combined biopsies as the reference standard. CONCLUSIONS: Combination of bpMRI with PSAd improves diagnostic accuracy and predictive values for sPCa detection in biopsy-naïve men. Restricting biopsies to men with highly suspicious bpMRI findings (score ≥4) or PSAd ≥0.15ng/ml/cc was the best biopsy strategy in our patient cohort, effectively balancing risks and benefits. Studies are needed to validate our findings in other patient populations. PATIENT SUMMARY: This report shows that biopsy-naïve men with clinical suspicion of prostate cancer who have low- or equivocal-suspicion biparametric magnetic resonance imaging results and a low prostate-specific antigen density may not require immediate prostate biopsies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Boesen L, Nørgaard N, Løgager V, et al. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men. Eur Urol Oncol. 2018. PMID: 31200846. doi:10.1016/j.euo.2018.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。